Novartis has announced encouraging results from two pivotal studies involving its experimental drug, ianalumab, targeting two different autoimmune indications. As reported by BioPharma Dive, the Swiss pharmaceutical company revealed positive data…
Fostamatinib is a spleen tyrosine kinase (SYK) inhibitor recommended to treat ITP patients who have been unable to receive a sufficient response from other medications. TAVLESSE® (fostamatinib), developed by Grifols…
The FDA has approved a new therapy for chronic immune thrombocytopenia (ITP). This treatment is an oral therapy to be taken with food, created by Dova Pharmaceuticals. It is called…
The US Food and Drug Administration (FDA) has just approved a new drug called Tavalisse™ to treat adults who have thrombocytopenia as a result of chronic immune thrombocytopenia (ITP), following…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
